#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant:

Ramnarayan et al.

Serial No.:

09/704,362

Customer No. 24961

Confirmation No.: 4748

Filed:

November 1, 2000

For:

USE OF COMPUTATIONALLY DERIVED

PROTEIN STRUCTURES OF GENETIC

POLYMORPHISMS IN

PHARMACOGENOMICS FOR DRUG

DESIGN AND CLINICAL APPLICATIONS

Art Unit:

1631

Examiner:

Brusca, J.

#### CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number

EV 338078285 US

Date of Deposit October 3, 2003

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 C.F.R.

§1.10 on the date indicated above and addressed

Mail Stop RCE

**Commissioner for Patents** 

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313

**ATTACHMENTS** 

Supplemental Information Disclosure Statement, Form PTO-1449, copies of three (3) citations

RECEIVED

OCT 0 8 2003

**TECH CENTER 1000/2000** 

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ramnarayan et al.

Serial No.: 09/704,362 Confirmation No.: 4748 Customer No. 24961

Filed:

November 1, 2000

For: USE OF COMPUTATIONALLY DERIVED

PROTEIN STRUCTURES OF GENETIC

POLYMORPHISMS IN

PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS

Art Unit:

1631

Examiner:

Brusca, J.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number EV 338078285 US Date of Deposit October 3, 2003

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and addressed

Mail Stop RCE

Commissioner for Patents U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313

Jopannan Ong

PECEIVED

OCT O 8 2003

ECH CENTER 1800/2900 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98

Mail Stop RCE

Commissioner for Patents U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application, the filing fee of \$180 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information

10/07/2003 DTESSEM1 00000071 09704362

03 FC:1806

180.00 OP

U.S.S.N. 09/704,362 Ramnarayan *et al.* Supplemental Information Disclosure Statement

Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and cited references are provided herewith.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted, Heller Ehrman White & McAuliffe LLP

By:\_

Stephanie L. Seidman Registration No. 33,779

Attorney Docket No. 24737-1906B
Address all correspondence to:
Heller Ehrman White & McAuliffe LLP
Stephanie L. Seidman, Esq.
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: (858) 450-8400

Facsimile: (858) 450-8400 Facsimile: (858) 587-5360 EMAIL sseidman@HEWM.com

														She	et 1 of 1
FORM PTO-1449									ATTY. DOCKET NO. 24737-1906B			SERIAL NO. 09/704,362		CONFIRM NO. 4748	
APPC CANT'S INFORMATION DISCLOSURE STATEMENT  If an addrisk is placed beside the reference number, a copy is North a prior application that is identified in the statement and relative Derwent English language abstract and/or English translation pro  U.S. PATI  EXAMINER *Ref. DOCUMENT NUMBER INITIAL Code									APPLICAN <sup>*</sup> Ramnaraya	et al.	CUSTOMER NO. 24961				
STATEMENT								FILING DATE November 1, 2000			GROUP 1631				
If an arterisk	is placed bapplication	eside that is	the ref	erence ied in	numb the st	oer, a atemer	copy internal	s NOT relied	provided bec	aus	se the referentier filing date	ce was pr under 35	eviously cite	ed to or sul	omitted to
Derwent Eng	llish langua	ge abs	tract a	nd/or	Englisi	h trans	slation PA	provid	ded. IT DOCUI	ΝΔΙ	FNTS		TECH	OCT 08	2003
EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE		NAME		CLASS	SUB CLASS	500/200
	Α	6	1	2	5	2	3	5	09/06/00		Padilla et al.		395	500.32	06/10/9
					F00	FIGURE			IT DOOL		IENTO				
EXAMINER INITIAL	*Ref. Code	FOREIGN PATI							DATE	Т	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
NONE															
			f 												
_ <del></del>															
	ОТ	HER	AR	Γ (In	clud	ing	Autł	nor,	Title, Da	te,	, Pertiner	ıt Page	es, Etc.)		
	В										by the Opt tional Physi				
	С	Dud and	ek <i>et</i> Glob	<i>al.</i> , al En	"Prot	ein S Mini	Struct mizat	ure f	Prediction U	Jsi ur	ng a Comb	ination o	of Sequei	nce Homo tational	ology

### **EXAMINER**

# DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Chemistry, 19(5):548-573 (1998)

Title: